From epistaxis to bone pain-report of two cases illustrating the clinicopathological spectrum of phosphaturic mesenchymal tumour with fibroblast growth factor receptor 1 immunohistochemical and cytogenetic analyses

Histopathology

Volumn 68, Issue 6, 2016, Pages 925-930

  Mok, Yingting ^a   Lee, Jen Chieh ^b   Lum, Jeffrey Huey Yew ^a   Petersson, Fredrik ^a  

^a NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Hypophosphataemia; Oncogenic osteomalacia; Paraneoplasia; Phosphaturia; Phosphaturic mesenchymal tumour; Tumour induced rickets

Indexed keywords

25 HYDROXYVITAMIN D; ANTIBIOTIC AGENT; FIBROBLAST GROWTH FACTOR 23; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FIBRONECTIN; FIBRONECTIN 1; PHOSPHATE; UNCLASSIFIED DRUG; FGFR1 PROTEIN, HUMAN;

ADIPOCYTE; ADULT; ANOSMIA; ANTIBIOTIC RESISTANCE; ARTICLE; BONE PAIN; CANCER LOCALIZATION; CANCER SURGERY; CASE REPORT; CELL MATURATION; CELL PROLIFERATION; CELL SHAPE; CHROMOGENIC IN SITU HYBRIDIZATION; CLINICAL FEATURE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONNECTIVE TISSUE TUMOR; CYTOGENETICS; DISEASE COURSE; DISEASE DURATION; EPISTAXIS; FEMUR DIAPHYSIS; FOLLOW UP; GENE FUSION; GENE OVEREXPRESSION; GENOMIC IN SITU HYBRIDIZATION; GIANT CELL; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERTENSION; HYPOCALCEMIA; HYPOPHOSPHATEMIA; IMMUNOHISTOCHEMISTRY; KIDNEY TUBULE ABSORPTION; KNEE PAIN; LABORATORY TEST; MALE; MEDICAL HISTORY; MESENCHYMOMA; MIDDLE AGED; MITOSIS RATE; MUSCLE WEAKNESS; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOGENIC OSTEOMALACIA; OPEN REDUCTION; OSTEOMALACIA; OSTEOSYNTHESIS; PALLIATIVE THERAPY; PHOSPHATE URINE LEVEL; PHOSPHATURIC MESENCHYMAL TUMOR; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN EXPRESSION; RARE DISEASE; RECURRENT DISEASE; TREATMENT OUTCOME; TREATMENT RESPONSE; UPREGULATION; VITAMIN BLOOD LEVEL; BONE TUMOR; CHROMOSOME ANALYSIS; COMPLICATION; GENETICS; NOSE CAVITY; NOSE TUMOR; PAIN; PATHOLOGY; SOFT TISSUE TUMOR;

BONE NEOPLASMS; CYTOGENETIC ANALYSIS; EPISTAXIS; HUMANS; HYPOPHOSPHATEMIA; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NASAL CAVITY; NOSE NEOPLASMS; PAIN; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; SOFT TISSUE NEOPLASMS;

EID: 84949643860     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.12872     Document Type: Article

References (26)

1. Chong WH, Molinolo AA, Chen CC, Collins MT. Tumor-induced osteomalacia. Endocr. Relat. Cancer 2011; 18; R53-R77.
2. Farrow EG, White KE. Tumor-induced osteomalacia. Expert. Rev. Endocrinol. Metab. 2009; 4; 435-442.
3. Weidner N, Santa Cruz D. Phosphaturic mesenchymal tumors. A polymorphous group causing osteomalacia or rickets. Cancer 1987; 59; 1442-1454.
4. Folpe AL, Fanburg-Smith JC, Billings SD et al. Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature. Am. J. Surg. Pathol. 2004; 28; 1-30.
5. ADHR Consortium. Autosomal dominant hypophosphataemic rickets is associated with mutations in fgf23. Nat. Genet. 2000; 26; 345-348.
6. Liu S, Gupta A, Quarles LD. Emerging role of fibroblast growth factor 23 in a bone-kidney axis regulating systemic phosphate homeostasis and extracellular matrix mineralization. Curr. Opin. Nephrol. Hypertens. 2007; 16; 329-335.
7. Lee JC, Jeng YM, Su SY et al. Identification of a novel FN1-FGFR1 genetic fusion as a frequent event in phosphaturic mesenchymal tumour. J. Pathol. 2015; 235; 539-545.
8. Carter JM, Caron BL, Dogan A, Folpe AL. A novel chromogenic in situ hybridization assay for FGF23 mRNA in phosphaturic mesenchymal tumors. Am. J. Surg. Pathol. 2015; 39; 75-83.
9. Peterson NR, Summerlin DJ, Cordes SR. Multiple phosphaturic mesenchymal tumors associated with oncogenic osteomalacia: case report and review of the literature. Ear Nose Throat J. 2010; 89; E11-E15.
10. Shelekhova KV, Kazakov DV, Michal M. Sinonasal phosphaturic mesenchymal tumor (mixed connective tissue variant): report of 2 cases. Am. J. Surg. Pathol. 2010; 34; 596-597.
11. Gardner KH, Shon W, Folpe AL, Wieland CN, Tebben PJ, Baum CL. Tumor-induced osteomalacia resulting from primary cutaneous phosphaturic mesenchymal tumor: a case and review of the medical literature. J. Cutan. Pathol. 2013; 40; 780-784; quiz 779.
12. Mathis DA, Stehel EJ Jr, Beshay JE, Mickey BE, Folpe AL, Raisanen J. Intracranial phosphaturic mesenchymal tumors: report of 2 cases. J. Neurosurg. 2013; 118; 903-907.
13. Harvey JN, Gray C, Belchetz PE. Oncogenous osteomalacia and malignancy. Clin. Endocrinol. (Oxf) 1992; 37; 379-382.
14. Tsujimura T, Sakaguchi K, Aozasa K. Phosphaturic mesenchymal tumor, mixed connective tissue variant (oncogenic osteomalacia). Pathol. Int. 1996; 46; 238-241.
15. Kumar R. New insights into phosphate homeostasis: fibroblast growth factor 23 and frizzled-related protein-4 are phosphaturic factors derived from tumors associated with osteomalacia. Curr. Opin. Nephrol. Hypertens. 2002; 11; 547-553.
16. Clugston E, Gill AC, Graf N, Bonar F, Gill AJ. Use of immunohistochemistry for SSTR2A to support a diagnosis of phosphaturic mesenchymal tumour. Pathology 2015; 47; 173-175.
17. Graham R, Krishnamurthy S, Oliveira A, Inwards C, Folpe AL. Frequent expression of fibroblast growth factor-23 (FGF23) mRNA in aneurysmal bone cysts and chondromyxoid fibromas. J. Clin. Pathol. 2012; 65; 907-909.
18. Houang M, Clarkson A, Sioson L et al. Phosphaturic mesenchymal tumors show positive staining for somatostatin receptor 2A (SSTR2A). Hum. Pathol. 2013; 44; 2711-2718.
19. Dienstmann R, Rodon J, Prat A et al. Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors. Ann. Oncol. 2014; 25; 552-563.
20. Xiao S, Nalabolu SR, Aster JC et al. FGFR1 is fused with a novel zinc-finger gene, ZNF198, in the t(8;13) leukaemia/lymphoma syndrome. Nat. Genet. 1998; 18; 84-87.
21. Graham RP, Hodge JC, Folpe AL et al. A cytogenetic analysis of 2 cases of phosphaturic mesenchymal tumor of mixed connective tissue type. Hum. Pathol. 2012; 43; 1334-1338.
22. Sidell D, Lai C, Bhuta S, Barnes L, Chhetri DK. Malignant phosphaturic mesenchymal tumor of the larynx. Laryngoscope 2011; 121; 1860-1863.
23. Uchihashi K, Nishijima-Matsunobu A, Matsuyama A et al. Phosphaturic mesenchymal tumor, nonphosphaturic variant, causing fatal pulmonary metastasis. Hum. Pathol. 2013; 44; 2614-2618.
24. Uramoto N, Furukawa M, Yoshizaki T. Malignant phosphaturic mesenchymal tumor, mixed connective tissue variant of the tongue. Auris Nasus Larynx 2009; 36; 104-105.
25. Ogose A, Hotta T, Emura I et al. Recurrent malignant variant of phosphaturic mesenchymal tumor with oncogenic osteomalacia. Skeletal Radiol. 2001; 30; 99-103.
26. Katoh M, Nakagama H. FGF receptors: cancer biology and therapeutics. Med. Res. Rev. 2014; 34; 280-300.